RFK Jr. wants to change program that stopped vaccine makers from leaving US market

In a significant move just months after assuming leadership of the federal health agency, Robert F. Kennedy Jr. is pushing for a substantial revision of a critical program that supports the nation’s childhood vaccination framework. His proposed changes could have far-reaching implications. At the forefront of his agenda is the Vaccine Injury Compensation Program (VICP), which offers swift and equitable compensation for individuals who experience rare but severe side effects from vaccinations, all without needing to prove negligence on the part of manufacturers. Established by Congress in the 1980s, the program was a response to the exodus of vaccine producers from the market due to litigation. Funded by a special tax on vaccines, this initiative provides manufacturers with legal protections that limit the potential for large monetary judgments against them in civil suits. Kennedy, an outspoken critic of the pharmaceutical industry and founder of an anti-vaccination organization, has previously claimed that the VICP diminishes the incentive for vaccine manufacturers to prioritize safety. In a recent interview with Tucker Carlson, he expressed concerns about alleged corruption within the program and announced that he has assembled a team to redesign it and broaden the criteria for those eligible for compensation. While specific details of his plans remain vague, he reiterated debunked assertions linking vaccines to autism and hinted, without providing evidence, that they may also contribute to various chronic health issues, including diabetes and narcolepsy. There are numerous ways his actions could destabilize the program, potentially leading to a scenario where vaccine manufacturers reconsider their participation in the U.S. market, reminiscent of the situation in the 1980s. For instance, if the government were to authorize payments for common health conditions that Kennedy has identified, the trust fund responsible for compensation could face depletion. Alternatively, he could systematically remove certain vaccines from the program’s coverage, thereby exposing their manufacturers to the types of lawsuits that previously drove them away from the industry.